Scholarlink

<p>The immune system undergoes profound age-related changes that manifest as impaired immune function (immunosenescence) and chronic low-grade inflammation (inflammaging), both of which may influence the tumor biology of head and neck squamous cell carcinoma. While phenotypic analyses of peripheral and intratumoral immune cells have so far shown few age-associated differences, omics studies have identified senescence-related signatures linked to poor prognosis and reduced immune activity. Emerging translational data suggest that senolytic therapies may overcome mechanisms of immunosenescence-driven resistance to immune checkpoint inhibitors. Clinical trials and real-world evidence consistently demonstrate that current immunotherapies are effective and well tolerated in older patients. Overall, biological age—captured, for example, through geriatric frailty assessments or molecular markers—appears more relevant for tumor biology and therapeutic decision-making than mere chronological age.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunologie des Alterns bei Kopf-Hals-Karzinomen

  • 期刊论文

  • 发表日期：

    2026年3月31日

查看全文
  • C. H. L. Kürten,
  • T. Peis,
  • L. Boosfeld,
  • M. Peis,
  • S. Lang

摘要

The immune system undergoes profound age-related changes that manifest as impaired immune function (immunosenescence) and chronic low-grade inflammation (inflammaging), both of which may influence the tumor biology of head and neck squamous cell carcinoma. While phenotypic analyses of peripheral and intratumoral immune cells have so far shown few age-associated differences, omics studies have identified senescence-related signatures linked to poor prognosis and reduced immune activity. Emerging translational data suggest that senolytic therapies may overcome mechanisms of immunosenescence-driven resistance to immune checkpoint inhibitors. Clinical trials and real-world evidence consistently demonstrate that current immunotherapies are effective and well tolerated in older patients. Overall, biological age—captured, for example, through geriatric frailty assessments or molecular markers—appears more relevant for tumor biology and therapeutic decision-making than mere chronological age.